Carcinogenicity study with @entity21639 in XXXX .

@entity72013 @entity21639 @entity5 @entity3014 @entity133 @entity358 @entity460 @entity35 @entity16774
Solutions of @entity21639 were administered to @entity35 by intratracheal instillations over a period of 30 months. Dosage was 0.01, 0.05 or 0.25 mg/kg, five times a week, or 0.05, 0.25 or 1.25 mg/kg once a week. Each group consisted of 40 male and 40 female @entity35 . Groups left untreated or given saline served as negative controls. The highest chromate dose proved to be within the range of the maximum tolerable amount. The main determinant of effect was the concentration of @entity16774 instilled, not the total dose per week. Non-neoplastic @entity358 , which occurred predominantly in the highest dose group, were fibrotic regions containing residual distorted bronchiolar lumens or cellular inflammatory foci containing alveolar macrophages, proliferated epithelium and chronic inflammatory thickening of @entity133 . Fourteen @entity35 given 1.25 mg/kg @entity21639 had a total of 20 @entity5 (12 benign, 8 malignant). One @entity35 given 0.25 mg/kg once a week had a @entity5 . @entity5 were generally small and were non-fatal. A comparable solution of @entity460 chromate, which was tested at the two highest dose levels, had virtually the same effect. The positive controls, @entity3014 and @entity72013 , induced a high rate of fatal @entity5 in the respiratory tract.
